[1]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230-233.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
　Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(04):230-233.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
点击复制

利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2015年04
页码:
230-233
栏目:
论著
出版日期:
2015-07-20

文章信息/Info

Title:
Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats
作者:
潘道延; 沈洁; 朱筱; 赵德福; 陈志; 韩亚娟; 李文婷; 陈远程
300202　天津市河西区妇产科医院产科
Author(s):
Pan Daoyan; Shen Jie; Zhu Xiao; Zhao Defu; Chen Zhi; Han Yajuan; Li Wenting; Chen Yuancheng.
Department of Endocrinology and Metabolism，The Third Affiliated Hospital of Southern Medical University，Guangzhou 510630，China Corresponding author：Shen Jie，Email：shenjiedr@163.com
关键词:
利格列汀; 2型糖尿病; 代谢性内毒素血症; 炎症
Keywords:
Linagliptin; Type 2 diabetes mellitus; Metabolic endotoxemia; Inflammation
DOI:
10.3760/cma.j.issn.1673-4157.2015.04.004
摘要:
目的　探讨利格列汀对高脂饮食联合小剂量链脲佐菌素（STZ）诱导的2型糖尿病大鼠代谢性内毒素血症的影响。方法　30只健康雄性Sprague-Dawley大鼠按随机数字法选择10只作为正常对照组，以正常饲料喂养，其余20只以高脂饲料饲喂8周后，予一次性腹腔注射STZ（35 mg/kg）制备2型糖尿病模型。将造模成功大鼠共16只按随机数字法分为利格列汀干预组（3 mg·kg-1·d-1灌胃，n=8）和糖尿病对照组（等量生理盐水灌胃，n=8），干预4周后测定大鼠空腹血糖、空腹胰岛素（FINS）、甘油三酯、总胆固醇、门静脉血浆脂多糖、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、二胺氧化酶（DAO）的水平，计算稳态模型评估-胰岛素敏感指数（HOMA-ISI）及稳态模型评估-胰岛素抵抗指数（HOMA-IR）。结果　与正常对照组相比，糖尿病对照组空腹血糖、FINS、HOMA-IR、甘油三酯、总胆固醇及体重等指标明显升高，ln（HOMA-ISI）明显降低，而利格列汀干预组上述指标除体重外较糖尿病对照组均有改善（F =39.18~136.74，P均＜0.01）。糖尿病对照组门静脉血浆脂多糖、TNF-α、IL-6、血浆DAO水平明显高于正常对照组，而利格列汀干预组上述指标较糖尿病对照组有所下降（F =18.13~51.43，P均＜0.05）。结论　利格列汀可以改善高脂饮食联合STZ诱导的2型糖尿病大鼠代谢性内毒素血症，并减轻全身系统性炎性反应。
Abstract:
Objective　To investigate the effects of linagliptin on metabolic endotoxemia in rats with type 2 diabetes mellitus（T2DM） induced by high fat feeding and low dose streptozotocin（STZ）. Methods　Ten of the 30 healthy male Sprague-Dawley rats were selected as normal control group according to random number and received basic diet，whereas the other 20 rats were fed with high-fat diet for 8 weeks and then treated with STZ intraperitoneal injection （35 mg/kg） once to induce T2DM. Diabetes was successfully induced in 16 rats which were then randomly divided into linagliptin treatment group（3 mg·kg-1·d-1 gavage，n=8） and T2DM control group（equivalent normal saline，n=8） according to random number. Four weeks later，fasting blood glucose，fasting blood insulin（FINS），triglyceride，total cholesterol，portal blood plasma lipopolysaccharide（LPS），tumor necrosis factor-α（TNF-α），interleukin 6（IL-6） and diamine oxidase（DAO） were measured. Homeostasis model assessment-insulin sensitive index （HOMA-ISI） and homeostasis model assessment-insulin resistance index（HOMA-IR） were calculated. Results　Compared with normal control group，the levels of fasting blood glucose，FINS，HOMA-IR，triglyceride，total cholesterol and body weight were all significantly increased in T2DM control group，whereas the ln（HOMA-ISI） was signifi-cantly reduced； compared with T2DM group，indexes mentioned above except body weight were all improved in linagliptin treatment group（F =39.18-136.74， all P ＜0.01）；compared with normal control group，the levels of portal blood plasma LPS，TNF-α，IL-6 and plasma DAO increased in T2DM control group，but indexes mentioned above were all decreased in linagliptin treatment group（F =18.13-51.43， all P＜0.05）. Conclusion　Linagliptin can improve the metabolic endotoxemia in rats with T2DM induced by high fat feeding and STZ，and attenuate systemic inflammation response.

参考文献/References:

[1]　Cani PD，Amar J，Iglesias MA，et al.Metabolic endotoxemia initiates obesity and insulin resistance[J].Diabetes，2007，56（7）：1761-1772. 　
[2]　Cani PD，Osto M，Geurts L，et al.Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity[J].Gut Microbes，2012，3（4）：279-288. 　
[3]　Cani PD，Bibiloni R，Knauf C，et al.Changes in gut microbiota control metabolic endotoxemia inflammation in high-fat diet-induced obesity and diabetes in mice[J].Diabetes，2008，57（6）：1470-1481. 　
[4]　Kern M，Kl?觟ting N，Niessen HG，et al.Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity[J].PLoS One，2012，7（6）：e38744. 　
[5]　Schürmann C，Linke A，Engelmann-Pilger K，et al.The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice[J].J Pharmacol Exp Ther，2012，342（1）：71-80. 　
[6]　Davidson EP，Coppey LJ，Holmes A，et al.Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats[J].Eur J Pharmacol，2012，677（1-3）：180-187. 　
[7]　Thomas L，Eckhardt M，Langkopf E，et al.（R）-8-（3-amino-piperidin-1-yl）-7-but-2-ynyl-3-methyl-1-（4-methyl-quinazolin-2-ylmethyl）-3，7-dihydro-purine-2，6-dione（BI 1356），a novel xanthine-based dipeptidyl peptidase 4 inhibitor，has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors[J].J Pharmacol Exp Ther，2008，325（1）：175-182. 　
[8]　Cani PD.Gut microbiota and obesity：lessons from the micro-biome[J].Brief Funct Genomics，2013，12（4）：381-387. 　
[9]　McNelis JC，Olefsky JM.Macrophages，immunity，and metabolic disease[J].Immunity，2014，41 （1）：36-48.
[10]　Ghoshal S，Witta J，Zhong J，et al.Chylomicrons promote intestinal absorption of lipopolysaccharides[J].J Lipid Res，2009，50（1）：90-97.
[11]　Shen W，Gaskins HR，McIntosh MK. Influence of dietary fat on intestinal microbes，inflammation，barrier function and metabolic outcomes[J].J Nutr Biochem，2014，25（3）：270-280.
[12]　Wang JH，Bose S，Kim GC，et al.Flos Lonicera ameliorates obesity and associated endotoxemia in rats through modulation of gut permeability and intestinal microbiota[J].PLoS One，2014，9（1）：e86117.
[13]　Luk GD，Bayless TM，Baylin SB.Plasma postheparin diamine oxidase.Sensitive provocative test for quantitating length of acute intestinal mucosal injury in the rat[J].J Clin Invest，1983， 71（5）：1308-1315.
[14]　Matikainen N，M?覿ntt?覿ri S，Schweizer A，et al.Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes[J].Diabetologia，2006， 49（9）：2049-2057.
[15]　Zhao Y，Yang L，Zhou Z.Dipeptidyl peptidase-4 inhibitors： multitarget drugs，not only antidiabetes drugs[J].J Diabetes，2014，6（1）：21-29.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
　Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
　Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(04):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
　Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(04):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
　Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(04):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
　Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
　Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
[10]申翘璇,陈国芳,张丹毓,等.自然疗法治疗2型糖尿病的研究进展[J].国际内分泌代谢杂志,2015,(04):280.[doi:10.3760/cma.j.issn.1673-4157.2015.04.018]
　Shen Qiaoxuan,Chen Guofang,Zhang Danyu,et al.Update on naturopathic therapy for type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):280.[doi:10.3760/cma.j.issn.1673-4157.2015.04.018]

备注/Memo

备注/Memo:
基金项目：广东省科技计划项目（2011B010500027）；广东省自然科学基金资助项目（S2013010016045） 　　通信作者：沈洁，Email: shenjiedr@163.com
更新日期/Last Update: 2015-07-20